Clinical Endorphin Deficiency
A state of insufficient endogenous opioid (endorphin) activity that disrupts hormonal signaling involved in ovulation, immune regulation, and reproductive function. Endorphins modulate the hypothalamic-pituitary axis, influencing GnRH pulsatility and downstream LH and FSH secretion. Deficient endorphin tone is associated with irregular cycles, poor follicular response, and implantation failure in some populations.
The condition lacks a standardized diagnostic threshold. In NeoFertility protocols, clinical endorphin deficiency is inferred from the clinical pattern: reduced ovarian responsiveness, thin endometrium, and failure to conceive despite otherwise normal-appearing diagnostics. Low-dose naltrexone at 4.5 mg nightly addresses this by transiently blocking opioid receptors. The temporary blockade triggers a compensatory rebound in endorphin production. See Low-Dose Naltrexone (LDN) for the mechanism and published outcomes data.
This is an area where RRM practice is ahead of the published literature. The physiological rationale is established. Large controlled trials do not yet exist. Clinicians using LDN for this indication are making a clinically reasoned judgment from mechanism, case series, and cohort data. That is honest medicine. It is also different from saying the question is settled.
This content is for educational purposes only and does not constitute medical advice. Consult an RRM clinician or healthcare provider for guidance specific to your situation.